Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)

Autor: Dima, Danai, Davis, James, Ahmed, Nausheen, Sannareddy, Aishwarya, Shaikh, Hira, Shune, Leyla, Kaur, Gurbakhash, Khouri, Jack, Afrough, Aimaz, Strouse, Christopher Sun, Lochner, Jonathan, Mahmoudjafari, Zahra, Raza, Shahzad, Valent, Jason, Anderson, Larry D., Jr., Anwer, Faiz, Hashmi, Hamza, Abdallah, Al-Ola
Zdroj: In Transplantation and Cellular Therapy February 2024 30(2) Supplement:S384-S385
Databáze: ScienceDirect
Externí odkaz: